We are all affected by pain, which is chronic in 1 in 5 people across the globe. Today one third of the global market for pain relief is taken up by opioids, with a high risk of dependence, overdoses, and deaths, a major public health issue.
Tafalgie Therapeutics is a JEI biotech company (a spin-off of IBDM, a CNRS-AMU research unit) specialising in the pharmaceutical development of next-generation, non-opioid active pharmaceutical ingredients for pain management. It has produced the first treatment that relieves and prevents the appearance of acute and chronic pain (inflammatory, postoperative, neuropathic) — with no dependence or tolerance issues — and that is truly ground-breaking innovation in terms of its mechanism of action. Following on the research of Dr. Moqrich (recipient of a 2010 ERC grant), Tafalgie enjoys exceptional published preclinical results as well as the expertise of an internationally — recognised scientific advisory board including Professor Patapoutian (2021 Nobel Prize winner), and is among the rare companies to have received a prestigious EIC grant in 2023 (5,500 applicants, 47 recipients).
